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Natural killer (NK) cells are lymphocytes whose
ability to identify and kill virally infected and malignant
cells while sparing normal cells was poorly understood
until the late 1980s and the introduction of the ‘‘miss-
ing-self’’ hypothesis. According to this hypothesis,
the down-regulation of major histocompatibility com-
plex (MHC) class I molecules during viral infection or
malignant transformation triggers NK cell activation
[1]. Since this hypothesis was first proposed, much
has been learned about NK cell surface receptors, their
role in the molecular basis of missing-self recognition,
and the mechanisms underlying NK cell tolerance. In
this review, we describe these mechanisms and discuss
the role of NK receptors in viral infection, tumor im-
munity, and stem cell transplantation (SCT).NK CELL RECEPTORS: KIR AND LY49
FAMILIES
Unlike T and B cell lymphocytes, which use rear-
ranged antigen-specific receptors, NK cells express
germline-encoded receptors comprising both inhibitory
and activating forms. The principal NK cell receptors in
humans are the killer cell immunoglobulin-like
receptors (KIRs), members of a polymorphic receptor1Howard Hughes Medical Institute, Rheumatology Divi-
Washington University Medical Center, St Louis, Mis-
2Ragon Institute of Massachusetts General Hospital,
chusetts Institute of Technology, and Harvard Univer-
Harvard Medical School, Boston, Massachusetts; and
rtment of Medicine, Memorial Sloan-Kettering Cancer
r, New York, New York.
isclosure: See Acknowledgments on page S103.
dence and reprint requests: Dr Katharine C. Hsu, Memo-
oan-Kettering Cancer Center, Department of Medicine,
York Ave, New York, NY 10021 (e-mail: hsuk@mskcc.
erican Society for Blood and Marrow Transplantation
/10/161S-0017$36.00/0
6/j.bbmt.2009.10.009family within the immunoglobulin superfamily. The
main NK cell receptors in mice are the C-type lectin-
like molecules belonging to the Ly49 family. In both
humans and mice, NK cells also express a lectin-like
receptor heterodimer consisting of CD94 coupled
with members of the NKG2 family. Interestingly, the
KIR molecules are type I integral membrane proteins,
whereas the lectin-like receptors have a type II mem-
brane orientation.
Most MHC-specific inhibitory NK cell receptors
recognize MHC class Ia molecules, although CD94/
NKG2 recognizes the MHC class Ib molecule Qa-1
in mice (HLA-E in humans), which presents signal
peptides from MHC class Ia molecules, thereby
achieving recognition of MHC class Ia expression
indirectly [2]. Constitutively expressed on healthy
cells, class I ligands of inhibitory receptors often are
down regulated during pathological states, such as
viral infection or transformation [3,4]. The immuno-
receptor tyrosine-based inhibitory motif (ITIM) in the
cytoplasmic tails of the inhibitory receptors associates
with the cytoplasmic tyrosine phosphatase SHP-1, but
may recruit other signaling molecules as well [5].
In a notable example of convergent evolution,
inhibitory human KIR receptors and mouse Ly49 re-
ceptors are functionally analogous, despite their differ-
ences in structure and membrane topology [6]. In
addition to MHC class I ligand binding and ITIM-
mediated inhibition, common features include consti-
tutive expression on unstimulated NK cells, stochastic
expression on overlapping NK subsets [7], expression
of one or more inhibitory receptors by an individual
NK cell [8], encoding by germline clusters of polymor-
phic genes [9,10], and close sequence and structure
homology to ITIM-negative activating receptors.
Structurally similar in the extracellular regions to the
corresponding inhibitory receptors, the activating
KIR and Ly49 receptors have short cytoplasmic tails
and associate with DAP12 or other immunoreceptor
tyrosine-based activation motif (ITAM)-containing
signaling molecules [2]. Whereas identified ligandsS97
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many activating receptors remain unknown. For the
activating receptor NKG2D, in which the ligands are
known, some constitutively expressed ligands can
become up regulated in response to stress or other
stimuli, resulting in ‘‘induced-self’’ in diseased cells
and enhanced NK cell activation [11].
Integration of inhibitory and activating receptor
signals determines the NK cell response to a target
cell. In detection of missing self-MHC on a target
cell, a decreased or absent inhibitory signal allows
the activation signal to dominate, triggering cytokine
production and/or cytotoxicity. Conversely, high
expression of an activating ligand on a target cell can
result in NK cell activation despite normal MHC
expression, although in general, inhibitory signals
typically predominate over activating signals.NK CELL SELF-TOLERANCE: EARLY MODELS
Over the past 2 decades, several models have been
proposed to explain NK cell function and tolerance
to self. The ‘‘missing-self’’ hypothesis described how
NK cells preferentially kill target cells lacking MHC
class I expression [1]; the ‘‘at least one’’ model proposed
that every NK cell expresses at least one inhibitory
receptor for self-MHC; and the receptor calibration
model suggested that differential expression of NK
receptors, depending on host expression of cognate
MHC class I ligand, translates to differences in func-
tional response. Despite some evidence in mice and
humans supporting each of these models, none of the
models can fully explain certain acknowledged find-
ings: NK cells from MHC-deficient mice are hypore-
sponsive [12], not hyperactive or autoreactive; NK
cells expressing receptors for which the host is lacking
the MHC class I ligand also are hyporesponsive, not
autoreactive; and a significant fraction of the NK reper-
toire expresses no known receptors for self-MHC and
yet are hyporesponsive.NK CELL LICENSING MODEL
In the ‘‘NK cell licensing’’ model, an NK cell that
has engaged self-MHC via MHC-specific receptors is
‘‘licensed’’ to be responsive to subsequent stimuli
received via their activation receptors [13,14]. Con-
versely, NK cells that do not engage self-MHC are
termed ‘‘unlicensed.’’ In mice, ironically, the MHC-
specific Ly49 receptors first identified as inhibitory
receptors for effector responses also mediate licensing.
The NK cell licensing model thus describes 2 popula-
tions of NK cells tolerant to self-MHC: NK cells that
are licensed for effector function through self-specific
MHC class I inhibitory receptors, but maintain self-
tolerance through direct inhibition via these samereceptors by self-MHC, and unlicensed NK cells that
lack self-specific MHC class I inhibitory receptors,
cannot engage self-MHC, and are inert to functionally
MHC-deficient host cells.
The licensing model was first proposed by Kim
et al. [13] in studies examining the responses of freshly
isolated NK cells on target cell-free antibody cross-
linking. Naı¨ve NK cells were stimulated with plate-
bound antibodies against NK cell activation receptors
such as NK1.1 (Nkrp1c) expressed on all immature
and mature NK cells in C57BL/6 (H2b) mice. Staining
for intracellular interferon (IFN)-g in conjunction
with surface staining for lineage markers and Ly49 re-
ceptors enabled assessment of NK cell activation at the
single cell level. Only NK cells expressing an inhibi-
tory receptor specific for self-MHC produced IFN-g
on ex vivo plate-bound antibody stimulation. Thus,
Ly49A1 NK cells from MHC-congenic or transgenic
mice expressing H2Dd, a ligand for Ly49A, were
licensed to produce IFN-g on stimulation; in contrast,
Ly49A1 NK cells from mice lacking an MHC ligand
for Ly49A, such as mice with the H2b haplotype,
were unlicensed and produced significantly less IFN-
g. NK cell production of other cytokines and NK
cytotoxicity produced consistent results, suggesting
that a receptor specific for self-MHC must be engaged
for the NK cell to be licensed for functional compe-
tence [13]. The licensing model was further supported
by a study in mice transgenic for only a single MHC
class I molecule, an H2Kb-ovalbumin peptide single
chain MHC class I trimer on an otherwise MHC class
I-deficient background, where the MHC class I trimer
is exclusively recognized by the Ly49C receptor [13].
Consistent with the licensing model, Ly49C1 NK
cells from these mice produced IFN-g on stimulation
with plate-bound anti-NK1.1, but Ly49C- NK cells
did not. Thus, through engagement of its inhibitory
receptor with its cognate MHC class I ligand,
expressed as self, an NK cell becomes functionally
competent to be triggered through its activation
receptors; that is, it becomes licensed.LICENSING OF HUMAN NK CELLS
Several subsequent studies have demonstrated that
licensing also applies to human NK cells. Approxi-
mately 10% of human CD56dim NK cells lack all
inhibitory receptors for self-MHC [15,16]. Consistent
with an unlicensed state, these cells exhibit reduced
cytokine production and cytotoxicity in response to
stimulation with MHC class I-negative target cells as
well as anti-CD16 crosslinking and antibody-depen-
dent cell-mediated cytotoxicity (ADCC). Despite their
hyporesponsiveness, they express normal protein
levels of perforin and granzyme and can respond to
phorbol myristate acetate (PMA) 1 ionomycin,
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execute effector functions. Conversely, NK cells
expressing inhibitory receptors for self-HLA-B and
-C alleles exhibit robust responses to class I-negative
target cells. Moreover, NK cells expressing more
than one inhibitory receptor for self-MHC demon-
strate even higher effector function, implying a dose
effect of surface inhibitory receptors for licensing [16].
Consequently, the functional NK repertoire is
defined by NK populations expressing an array of
inhibitory receptors within the context of self-MHC.
A hierarchy of effector function can be discerned in
which NK cells lacking all inhibitory receptors are
largely functionally inert, cells exclusively expressing
CD94/NKG2A display modest functional competence,
cells with a single inhibitory Ly49 or KIR receptor for
self-MHC display higher functional competence, and
cells with more than one inhibitory for self-MHC dis-
play progressively higher functional enhancement. In
humans, the NK repertoire tends toward a state of ‘‘in-
termediate inhibition,’’ with cells of lowest and highest
functional potency represented in lower numbers com-
pared with cells of intermediate potency [16,17]. Data
from mouse models also demonstrate a correlation
between different Ly49-MHC combinations and a di-
versity of NK functional potencies [18,19].
What is the role of unlicensed cells, which can be
identified in humans and mice and represent approxi-
mately 10% of all NK cells? Responding poorly to
stimulation with MHC class I-negative target cells or
plate-bound antibody, they still can produce IFN-g
when stimulated with PMA 1 ionomycin with similar
frequency to self-MHC-specific NK cells. Further-
more, there are no specific differences in developmen-
tal markers between licensed and unlicensed cells,
suggesting that unlicensed cells are not simply imma-
ture. Studies in mice have shown that in vivo poly-I:C
(polyinosinic:polycytidylic acid) treatment or in vitro
culture in IL-2 can circumvent the effect of licensing,
inducing unlicensed populations to respond to stimula-
tion [13,20]. The ability of cytokine stimulation in vitro
to reverse the hyporesponsiveness of unlicensed cells
suggests that similar effects on NK cells may occur in
vivo during the inflammatory states of viral infection
or malignancy. Indeed, NK cells in mixed wild-type
beta(2)-microglobulin-deficient [b2m(-/-)] chimeric
mice are initially tolerant of MHC class I-deficient
host cells, but readily reject host b2m(-/-) bone marrow
(BM) after infection with murine cytomegalovirus
(CMV), suggesting that the cytokine environment in the
inflammatory state associated with viral infection can
break established NK tolerance [21]. The role of NK cells
in viral infection and the relevance of breaking tolerance
to self in hematopoietic stem cell transplantation
(HSCT) are discussed in greater detail later in the article.
For licensing to occur, a self-MHC-specific recep-
tor must engage self-MHC. Moreover, it is known thatthe self-MHC-specific receptor itself is responsible for
directly signaling the licensing event. Gene transfer of
intact and mutant Ly49A receptors into HSC in BM
reconstitution studies have shown that the receptor
can confer licensing, when the cognate ligand is pres-
ent in the host, but only when the ITIM region in
the receptor is intact [13]. How the ITIM mediates
licensing is unknown, but it appears that the ITIM
can recruit more than just phosphatases, because re-
cent studies indicate that ITIM-dependent inhibitory
signaling results in the formation of macromolecular
complexes mediated by scaffolding proteins [22]. It is
possible that there are differences in these macromo-
lecular complexes during licensing.
Other than the requirement of physical interaction
between MHC class I with inhibitory NK receptors for
licensing to occur, where it occurs and with which
accessory cell(s) it occurs remain unclear. Several find-
ings suggest that NK cell licensing occurs during mat-
uration in the BM: expression of inhibitory receptors
occurs early in NK cell development [23] and coin-
cides with the acquisition of effector capacity [24,25],
NK cells with self-MHC-specific receptors proliferate
at a higher rate than NK cells without self-MHC-spe-
cific receptors [13], and BM NK cells undergo prolif-
eration before reaching full developmental maturity
[23]. Although no single cell type appears to be respon-
sible for NK cell licensing, both hematopoietic and
nonhematopoietic cell elements have been found to
play a role, with BM stromal cells likely contributing
[26–29]. Other studies suggest that NK cells also can
mature in the thymus, but this appears to apply to
a subset of NK cells just beginning to be studied
[30,31].OTHER CONTRIBUTORS TO NK
SELF-TOLERANCE
Other molecular and cellular elements may affect
the mechanisms underlying NK cell licensing and
self-tolerance. In mice, cis interaction between the
MHC-specific receptor with self-MHC on the NK
cell itself has been reported. These interactions likely
have consequences in the conformation of Ly49
homodimers, affecting the accessibility for MHC class
I binding in trans [32], and also may affect recruitment
of intracellular signaling molecules [33], ultimately
leading to modulation of NK cell function. The
requirement for simultaneous engagement of multiple
activation receptors to achieve full NK cell stimulation
provides another layer of protection from autoaggres-
sion [34]. The only apparent exception to this require-
ment is CD16 (FcgRIII), which binds ligand via
soluble IgG antibody, whose production by B cells is
subject to its own strict regulation [35]. Furthermore,
autoregulation mechanisms in NK cell activation
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sion [36], endocytosis and degradation of the acti-
vation receptor NKG2D [37], and induction of
cross-tolerance of other activation pathways [38,39].
Finally, certain cell-cell interactions provide acces-
sory activation signals to NK cells, whereas others
impart yet another tier of protection from autoaggres-
sion. Most likely through trans presentation of IL-15,
dendritic cell-mediated NK cell activation and recruit-
ment are important in tumor control as well as in the
NK cell response to malaria and viral infection [40–
42]. Less well studied is the activation of NK T cells,
which can trigger NK cell cytokine production. In
contrast, regulatory T cells can suppress NK cell acti-
vation, possibly via expression of membrane-bound
transforming growth factor b, leading to NK down-
regulation of the activating receptor NKG2D. Finally,
the NK cell population itself may have a regulatory
subset, capable of inhibiting IFN-g production and
cytotoxic function by other NK cells.NK CELLS AND HIV
NK cells are known to play an important role in the
control of viral infections, based largely on results from
studies in mice. Several studies, including recent stud-
ies in humans, have demonstrated that NK cells are ac-
tivated and expand significantly during the early stages
of viral infections, and that these early NK effectors
might limit viral replication during the early phases
of infection, before the development of antigen-
specific adaptive immune responses that eventually
allow for the control of the virus.
NK cells use several classes of receptors to monitor
for virally infected cells. In humans, these include the
KIR receptors, the NKG2 receptors, the natural cyto-
toxicity receptor family, and several other classes of
coreceptors. In addition, the CD16 (FcgRIII) receptor
allows NK cells to recognize and eliminate opsonized
pathogens or cells. NK cells can mediate their effector
function by a number of different mechanisms, includ-
ing (1) the secretion of antiviral cytokines, (2) exocy-
tosis of cytoplasmic granules containing perforin
and granzyme, (3) Fas ligand-mediated induction of
apoptosis, and (4) ADCC. In addition, NK cells
can directly modulate adaptive immune responses
through the secretion of cytokines and interaction
with dendritic cells.
The first evidence that NK cells play a critical role
in the immune response to viruses in humans arose
from a seminal case of a teenage girl with a complete
NK cell deficiency who experienced a sequence of
severe viral infections, including varicella, CMV pneu-
monia, and severe cutaneous herpes simplex virus
(HSV) infection [43]. Although NK cells were absent,
the patient had normal T cells, B cells, and neutrophils,providing direct evidence for a role of NK cells in the
control of herpes viral infections in humans. Some sub-
sequent studies have linked genetic defects in NK cell
function and development to increased susceptibility
to viral infection [44,45]. The critical role of NK cells
in the control of viral infections is further supported
by the observation that viruses have devised elaborate
mechanisms to subvert immune selection pressure
mediated by NK cells, including active suppression of
presentation of the stress molecules that can serve as
NK cell ligands on the surface of infected cells and
the expression of molecules that serve as ligands for
inhibitory NK cell receptors.
The strongest evidence for a role of NK cells in hu-
man immunodeficiency virus (HIV)-1 infection comes
from population studies assessing the role of polymor-
phisms in NK cell receptors on HIV-1 disease pro-
gression. The seminal epidemiologic study of Martin
et al. [46] was the first to demonstrate that individuals
who coexpress the activating KIR3DS1 allele in con-
junction with HLA class I alleles from the HLA-Bw4
family that encode an isoleucine at position 80
(referred to as HLABw480I) progressed significantly
more slowly toward AIDS than individuals with only
1 or neither of these 2 alleles. While the physical
interaction between the KIR3DS1 molecule and
HLABw480I molecules has not been shown, func-
tional studies have demonstrated that KIR3DS11
NK cells can respond potently to HIV-1-infected
Bw480I1CD41T cells and suppress viral replication
in these Bw480I1 cells [47]. Furthermore, studies in
HIV-1-infected individuals showed that NK cells de-
rived from individuals who have a copy of KIR3DS1
responded more potently to HLA class I-negative
target cells than NK cells from KIR3DS1-negative
subjects. Interestingly, although the expression of
KIR3DS1 alone was associated with a significantly
elevated NK cell response, the NK cell responses
were strongest in those individuals with both
KIR3DS1 and HLA-Bw480I [48]. Furthermore, new
evidence indicates that KIR3DS11 NK cells expand
preferentially during acute HIV-1 infection and persist
at elevated levels, but only in individuals who also
coexpress its putative ligand, HLA-Bw480I [49].
Finally, an increased proportion of KIR3DS1 homo-
zygotes were identified in persistently HIV-1-
negative but highly HIV-1-exposed individuals,
suggesting that KIR3DS1 also may be involved in
protection from infection [50]. Taken together, these
epidemiologic and functional data support a coopera-
tive interaction between KIR3DS1 and HLA-
Bw480I in the NK cell response to HIV infection.
The precise mechanism by which KIR3DS11 NK
cells can recognize HLA-Bw480I1 HIV-1-infected
cells, and the potential antigens presented by HLA-
Bw480I that might trigger this recognition, remain
to be elucidated.
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nity arises from examples of viral adaptation to evade
immune pressure. In an effort to evade adaptive
T cell immune responses, HIV-1 Nef down regulates
the expression of HLA-A and HLA-B molecules on
the surface of infected cells [51,52]; however, reduced
HLA class I expression can make these cells more sus-
ceptible to NK cell lysis through a lack of engagement
of inhibitory receptor-expressing NK cells. This indi-
cates that HIV-1 has evolved a means of maintaining
or even up-regulating on the surface of infected cells
the expression of HLA-C molecules, direct ligands
for a number of inhibitory KIRs, and, through HLA-
E, indirect ligands for the inhibitory NKG2-CD94
complex [53,54]. Thus, HIV-1 is able to evade
recognition by both CD81 T cells and NK cells by
down regulating HLA-A and HLA-B, whereas in-
creasing the expression of ligands for other inhibitory
NK receptors on the surface of infected cells.
HIV-1 may select for epitopes presented by HLA
class I on the surface of infected cells that might
either enhance the binding of inhibitory KIRs or
avoid recognition by activating KIRs. Several studies
have demonstrated that KIRs can discriminate be-
tween peptides presented by a number of HLA class
I alleles, including HLA-B27, HLA-Cw3, HLA-
Cw4, HLA-Cw7, and HLA-A3/A11, revealing the
critical role of specific residues of the HLA-presented
peptides in the peptide-specific interaction with KIR
[55–61]. These data demonstrate that the sequence of
the peptide presented by HLA class I molecules can
influence the ligation by inhibitory, and possibily
also activating, KIRs, thereby influencing target cell
lysis. This might place significant pressure on the
virus at specific residues and drive KIR-dependent
viral evolution.
Taken together, these data provide evidence
suggesting that NK cells play an important role in
the control of HIV-1 infection and might impose
immunologic selection pressure on the virus. Future
studies aimed at identifying the mechanisms by which
NK cells recognize HIV-1-infected cells, and how
HIV-1 has evolved to evade NK cell-mediated
immune selection pressure, will provide important
insights into the correlates of protective immunity in
HIV-1 and might aid in the design of immunologic
interventions aimed at enhancing NK cell-mediated
control of HIV-1 replication.NK CELLS AND HEMATOPOIETIC STEM CELL
TRANSPLANTATION
The role of NK cells in allogeneic hematopoietic
stem cell transplantation (HSCT) continues to gen-
erate interest as more data emerge on the signifi-
cance of NK cell immunogenetics on transplantationoutcome. NK cells robustly reconstitute the periph-
eral blood immediately following transplantation,
and historical studies have implicated NK cells
in the suppression of graft-versus-host disease
(GVHD), promoting BM engraftment, and exerting
a graft-versus-leukemia (GVL) effect. More recent
studies have described improved HSCT outcomes
with infusion of higher CD56dim/CD56bright NK ra-
tios in the allograft and more rapid NK cell recovery
immediately following transplantation [62,63]. With
an increased understanding of how NK receptor-
ligand interactions drive NK function, identifying
the molecular mechanisms underlying these clinical
and laboratory observations has become progressively
more feasible. In parallel, studies correlating NK im-
munogenetics with transplantation outcomes con-
tinue to provide additional insight into the function
of activating NK receptors, about which compara-
tively little is known and whose ligands remain
largely obscure.MISSING SELF IN HSCT
For the purposes of examining the clinical effects
of ‘‘missing self’’ by licensed NK cells, perhaps no
other clinical setting is more suitable than the HLA-
mismatched (or, more specifically, KIR ligand-mis-
matched) allogeneic HSCT. In this circumstance,
donor-derived licensed NK cells infused into patients
lacking the MHC class I ligands present in the donor
recognize the absence of donor MHC ligands on po-
tential target cells, leading to a lack of inhibition and
a lowered threshold for activation, enhanced clearance
of tumor cells, and improved outcomes. This model
was exemplified in studies by Ruggeri et al. [64], who
examined 60 high-risk leukemia patients undergoing
HLA haplotype-disparate HSCT and identified a miss-
ing-self relationship between donor and recipient
HLA genotypes predictive of donor NK alloreactivity,
culminating in a potential GVL effect [65]. In these
studies, donor and recipient HLA-B and HLA-C ge-
notypes were segregated according to their inhibitory
KIR ligand categories: the HLA-C1 alleles recognized
by KIR2DL2 and KIR2DL3 and characterized by
Ser77 and Asn80 (including, with rare exceptions,
HLA-Cw1, -Cw3, -Cw7, -Cw8, Cw14, and Cw16 al-
lotypes); the HLA-C2 alleles recognized by KIR2DL1
and characterized by Asn77 and Lys80 (including, with
rare exceptions, HLA-Cw2, -Cw4, -Cw5, -Cw6,
-Cw15, -Cw17, and -Cw18 allotypes); and the HLA-
B alleles with the Bw4 serologic epitope in the a1
domain, recognized by KIR3DL1. Since that study,
HLA-A alleles with the Bw4 epitope also have been
found to bind the inhibitory KIR3DL1 and confer a li-
censing effect [66,67]. Among the 60 donor-recipient
pairs studied, 20 fulfilled the conditions predictive of
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ent in the donor. Thus, NK cells from a donor who is
heterozygous for HLA-C group 1 and HLA-C group
2 ligands and who exhibits the inhibitory KIR recep-
tors for both HLA-C ligand groups, on transfer into
a recipient homozygous for HLA-C group 1, will be
released from inhibition by failure of the donor inhib-
itory KIR to engage its cognate HLA-C group 2 ligand.
A similar prediction could be made for a recipient lack-
ing the HLA-Bw4 epitope if his or her donor exhibits
a HLA-Bw4 allotype. Accordingly, alloreactive NK
cell clones could be isolated from a recipient in the first
3 months after HSCT only if the recipient lacked an
HLA epitope that was present in the donor (KIR
ligand incompatibility in a graft-versus-host vector).
Alloreactive NK cell lysis of recipient phytohemagglu-
tinin-stimulated blasts or B lymphocyte cell line
(BLCL) target cells corresponded with NK cell lysis
of leukemic blasts from the same individuals and could
be blocked by competitive incubation with target cells
expressing the absent allele group [65]. Furthermore,
the alloreactive NK clones isolated from patients could
effectively kill acute myelogenous leukemia (AML)
and chronic myelogenous leukemia (CML) target
cells, but could not reliably kill acute lymphoblastic
leukemia (ALL) target cells, revealing a disparity in
NK cell sensitivity between myeloid and lymphoid
leukemias. When the inverse HLA relationship existed
between donor and recipient predicting host-versus-
graft alloreactivity, graft rejection occurred only in
1 instance. A follow-up study of 112 HLA haplotype-
disparate transplantations confirmed that AML recip-
ients lacking donor self-specific KIR ligands from KIR
ligand-incompatible pairs had a lower incidence of re-
lapse and improved event-free survival (EFS) [68]. As
further evidence of an NK cell-mediated GVL effect,
the transfer of alloreactive NK clones into NOD/
SCID mice previously infused with human blastic
CML resulted in disease clearance and longer survival
compared with leukemic mice not infused with allor-
eactive NK clones. In a mouse model of mismatched
BM transplantation (F1 H-2
d/b /parent H-2b), infu-
sion of alloreactive NK cells permitted a mismatched
transplantation following reduced-intensity condi-
tioning (RIC), surprisingly without the development
of graft rejection or GVHD. These findings advanced
the possibility that donor-derived alloreactive NK
cells could prevent lethal GVHD by eliminating the
recipient antigen-presenting cells responsible for initi-
ating GVHD [64]. Investigations of the missing-self
effect in other HLA-mismatched transplantation pop-
ulations have yielded variable results [69,70], however,
indicating that the missing-self impact on HSCT
outcome may be most evident in specific disease
categories and under specific treatment conditions,
such as in vivo T-cell depletion with antithymocyte
globulin (ATG).MISSING KIR LIGAND IN HSCT
Is donor-recipient class I-mismatching necessary to
achieve an NK cell-mediated effect in HSCT? The
results of several studies indicate that beneficial NK
effects are possible even in HLA-matched HSCT in
which the donor has inhibitory KIR for which neither
the donor nor the recipient has the relevant class I ligand
[71–74]. In a study of 178 patients with AML, myelodys-
plastic syndrome (MDS), CML, or ALL who received
T cell-depleted allografts from HLA-identical siblings,
63% of the recipients lacked one or more HLA class I
ligands for the donor’s inhibitory KIR. Comparing
the survival and relapse rates in the recipients with and
without the ligand for donor inhibitory KIR revealed
that AML and MDS patients with a missing KIR ligand
had significantly improved overall and disease-free sur-
vival (DFS) secondary to a lower relapse rate. Further-
more, those recipients lacking more than 1 ligand for
donor inhibitory KIR exhibited a greater benefit in
overall and disease-free survival (DFS) than those who
lacked only 1 ligand, implying a dose effect of the lack
of KIR ligand [71]. Classically licensed NK cells in
this setting were not likely the mediators of the alloreac-
tive effect; because donors and recipients were HLA-
matched, the donors also lacked the same relevant class
I ligands for their inhibitory KIR, implying that these
non-self-specific KIR-expressing NK cells could not
be licensed for effector function. A recent study by Yu
et al. [75] has clarified this apparent incongruity, dem-
onstrating that in the first 3 months after HSCT, circu-
lating unlicensed NK cells with inhibitory KIR for
nonself HLA indeed exhibit effector function, display-
ing cytokine response and cytotoxicity toward tumor
target cells lacking the class I ligand for the inhibitory
KIR. In distinct contrast to the ‘‘missing-self’’ behavior
of licensed NK cells tolerized to self-HLA, these studies
demonstrate that in HSCT, unlicensed NK cells can cir-
cumvent the effects of licensing, break tolerance to self,
and function according to a less-restrictive ‘‘missing
HLA ligand’’ mechanism. Just as CMV infection can cir-
cumvent the effects of licensing in mice, conferring
effector function to otherwise unlicensed cells, HSCT
may provide an in vivo inflammatory cytokine milieu
that is conducive for breaking tolerance to self. The
cytokines capable of inducing activation of unlicensed
cells in vivo remain unknown, and may be elaborated
only in specific transplantation conditions, accounting
for inconsistencies in demonstrating the missing-ligand
effect in other transplantation populations [68,76].ACTIVATING DONOR KIR GENOTYPE AND
HSCTOUTCOME
Studies correlating donor activating KIR genotype
with HSCT outcome may ultimately help guide donor
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HSCTs, patients with donors exhibiting genotypes
with activating KIR2DS1 and 2DS2 had a decreased
relapse rate [77]. This finding was supported by a sub-
sequent study demonstrating direct lysis of HLA-C2
homozygous leukemic blasts by 2DS11 NK cells
[78]. In another study examining 448 AML patients,
a donor with a KIR B-haplotype was associated with
higher relapse-free survival, where KIR B-haplotypes
are generally characterized by more than 1 activating
KIR [79]. Most recently, Venstrom et al. [80] de-
scribed a decreased risk of grade II-IV GVHD in re-
cipients with donors exhibiting the activating
KIR3DS1. In findings that may inform laboratory
studies of innate immunity to viral infection, different
groups have described decreased CMV reactivation
with donor activating KIR [81]. Still other studies
have identified other activating KIRs with specific
combinations of inhibitory KIR-HLA as important
factors affecting GVHD, relapse, and survival.
Large-scale multicenter studies are needed to confirm
these findings and codify the exact KIR-HLA relation-
ships and transplantation conditions important for ex-
ploiting NK reactivity. Identifying the molecular
ligands for the activating KIR will help clarify the
mechanisms underlying these correlative studies.KIR-HLA ANDAUTOLOGOUS HSCT FOR
SOLID TUMORS
In settings of inflammation, such as infection or
allogeneic HSCT, normally hyporesponsive NK cells
can circumvent the effects of licensing and become
cytotoxic to hematologic targets lacking the HLA class
I ligand. Comparable cytokine conditions may exist af-
ter high-dose chemotherapy with autologous HSCT,
leading investigators to reason that NK cells stimulated
to behave according to a ‘‘missing ligand’’ also may
exhibit antitumor effects against solid tumors [82,83].
A recent retrospective analysis of KIR and HLA geno-
types in high-risk neuroblastoma patients undergoing
autologous HSCT showed improved outcomes in
patients lacking HLA class I ligand(s) for autologous
inhibitory KIR [83]. Highlighting the importance of
innate immunity in solid tumor control, these data
indicate that KIR-HLA immunogenetics may provide
a novel prognostic marker for high-risk neuroblastoma
and invite similar studies for other malignancies.CONCLUSION
NK cell receptors and ligands are vital to the
mechanisms underlying NK cell tolerance, which can
be altered in the setting of viral infection and HSCT.
Thus, receptor-ligand immunogenetics provides
a powerful tool for predicting NK cell alloreactivityfor both hematopoietic and solid tumor treatment out-
comes. An understanding of NK cell immunogenetics
and tolerance is essential for designing future therapies
involving adoptive NK cell therapy.ACKNOWLEDGMENTS
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